The histogram plot shows the proportion of patients with VTE with outcomes of recurrent VTE, major bleeding, and a composite of clinically relevant major and nonmajor bleeding.
The P values for all were derived from 3-way comparisons of the anticoagulant cohorts.

Note: No head-to-head clinical trials have been conducted comparing the efficacy and safety of DOACs versus DOACs. Data do not imply comparable efficacy, safety, or product interchangeability.